https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51883 Wed 28 Feb 2024 15:48:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55374 Wed 22 May 2024 15:07:38 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48386 2-agonist add-ons (54.1 vs 39.8%), and experienced significantly (P < .001) more exacerbations per year (median, 3 vs 2/y), worse asthma control, and worse lung function (% predicted postbronchodilator FEV1/forced vital capacity, 0.69 vs 0.72) versus nonreferred patients. Confirmed patients with severe asthma (ie, UK patients in the International Severe Asthma Registry) were younger (51 vs 65 years; P < .001), and significantly (P < .001) more likely to have uncontrolled asthma (91.4% vs 62.5%), a higher exacerbation rate (4/y [initial assessment] vs 3/y), use inhaled corticosteroid/long-acting β₂-agonist add-ons (67.7% vs 54.1%), and have nasal polyposis (24.2% vs 6.8) than referred patients with PSA. Conclusions: Large numbers of patients with PSA in the United Kingdom are underrecognized in primary care. These patients would benefit from a more systematic assessment in primary care and possible specialist referral.]]> Thu 16 Mar 2023 08:32:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52233 Thu 05 Oct 2023 11:40:17 AEDT ]]>